Synaptic dysfunction represents an early pathological event that precedes neurodegeneration in Alzheimer’s disease (AD), even though the molecular mechanisms that underlie synaptic dysfunction remain to be completely understood. Nonetheless, in vivo synaptic biomarkers are highly relevant as they have the potential to reveal early-stage changes and to track target engagement of specific disease-modifying strategies.
